MTMaxime Teisseyre

Maxime Teisseyre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maxime Teisseyre has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Céline Fernandez

    Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique et Glomérulonéphirte Extra-Membraneuse

    3 shared publications
  • Marion Cremoni

    CHU de Nice, Laboratoire D'immunologie et de Thérapie Cellulaire Nice France

    3 shared publications
  • Barbara Seitz-Polski

    2 shared publications
  • Barbara Seitz-Polski

    Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Nice, France

    2 shared publications
  • Vesna Brglez

    Institut de Recherche sur le Cancer et Vieillissement UMR7284 CNRS INSERM U1081, Université Côte d’Azur, Nice, Provence-Alpes-Côte d’Azur, France

    2 shared publications
  • Alan Moutou

    Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    Anticorps anti-rituximab dans les maladies auto-immunes et les hémopathies malignes : mise au point

    by Maxime Teisseyre, Marco Allinovi, Michael Levraut, Jacopo Lomi, Marion Cremoni, Barbara Seitz-Polski

  • Open Access

    Rituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction

    by Mounir El Maï, Maxime Teisseyre, Yousra Cheddadi, Vesna Brglez, Erendira Vazquez-Salazar, Sarah Nahon Carzo, Sami Addou, Kevin Zorzi, Marion Cremoni, Céline Fernandez, et al.

    Background: Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how rituximab influences Th cells and whether this impacts on clinical outcome. Methods: Th cell profile of MN patients was characterized using peripheral blood mononuclear cell samples from a multi-centre, prospective clinical trial. Th cell subsets (Treg, Th17 and Th1) were measured by flow cytometry at baseline and after rituximab treatment during a two years follow-up. In vitro studies on fresh peripheral blood samples and isolated cell populations were performed to investigate the mechanisms through which rituximab induces Treg cells. Findings: Before rituximab treatment, MN patients had a Th17/Treg imbalance when compared to age-matched healthy donors (p=0.004). Responders had significantly higher proportions of Treg cells post-rituximab than non-responders (p=0.037). In vitro , rituximab treatment induced Treg cells when using peripheral blood samples from MN patients, however the induction was lost when isolated T cells were used instead of whole blood (p=0.02). Rituximab did not directly induce Treg cells but required a specific cellular environment composed by at least B and Natural Killer (NK) cells as observed by treating pooled T, B and NK cells. Finally, using complementation assays, we demonstrated that rituximab-mediated Treg induction relied on cytokines, mainly Transforming growth factor β (TGFβ), secreted by activated NK cells. Interpretation: Rituximab induces Treg through cytokines produced by NK cells probably during the mechanism of B cell depletion by antibody-dependent cell-mediated cytotoxicity. This mechanism could potentiate the likelihood of remission in MN patients by counteracting loss of immune tolerance.

  • Open Access

    Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial

    by Maxime Teisseyre, Alexandre Destere, Marion Cremoni, Kévin Zorzi, Vesna Brglez, Sylvain Benito, Laurent Bailly, Céline Fernandez, Barbara Seitz-Polski

    Introduction Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy. However, Kidney Disease Improving Global Outcomes guidelines do not recommend any specific protocol. Rituximab bioavailability is reduced in patients with membranous nephropathy due to urinary drug loss. Underdosing of rituximab is associated with treatment failure. We have previously developed a machine learning algorithm to predict the risk of underdosing. We have retrospectively shown that patients with a high risk of underdosing required higher doses of rituximab to achieve remission. The aim of this prospective study is to evaluate the efficacy of algorithm-driven rituximab treatment in patients with membranous nephropathy compared to standard treatment. Methods A multicentre, randomised, controlled, open-label, prospective superiority clinical trial will be conducted in 13 French hospitals. 130 consecutive patients with primary membranous nephropathy and active nephrotic syndrome will be randomised to either the standard protocol control group (two 1 g rituximab infusions on days 0 and 15) or the algorithm-driven rituximab treatment group. In the latter, the rituximab dose will depend on the algorithm-estimated risk of underdosing. Patients with an algorithm-estimated risk of underdosing ≤50% will receive 1 g of rituximab on days 0 and 15. Patients with an algorithm-estimated risk of underdosing between 51% and 75% will receive 1 g of rituximab on days 0, 15 and 30. Finally, patients with an estimated risk of underdosing >75% will receive 1 g of rituximab on days 0, 15, 30 and 45. The primary study outcome is the rate of clinical remission (complete or partial) at month 6 after treatment initiation. The secondary outcomes include clinical remission at month 12, immunological remission, proteinuria, albuminuria, serum creatinine, estimated glomerular filtration rate, phospholipase A2 receptor type 1 antibody titre, anti-rituximab antibody occurrence, lymphocyte count, serum rituximab level and related adverse events. Ethics and dissemination The trial received ethics approval from the local ethics boards. The results of this study will confirm whether algorithm-driven rituximab treatment is more effective in inducing remission than the standard regimen and thus may contribute to improving management of patients with membranous nephropathy. The results of our study will be submitted to a peer-review journal. Trial registration number NCT06341205 trial number. Registered on 2 April 2024.


  • Open Access

    Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation

    by Marion Cremoni, Maxime Teisseyre, Olivier Thaunat, Céline Fernandez, Christine Payre, Alan Moutou, Hadi Zarif, Vesna Brglez, Laetitia Albano, Valérie Moal, et al.